Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise

Executive Summary

During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.

You may also be interested in...



Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

Pfizer Sets Its Sights On Therapeutic Cancer Vaccines

The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.

Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline

Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel